Commentary · 21 Feb 2026
Conference abstractPublished 10 Dec 2021
The nuclear translocation of ERK as a therapeutic target for cancer
Weizmann Institute of Science, Israel
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
A hallmark of MAPK signaling is the nuclear translocation of some of its components, which is necessary for their physiological/pathological functions. We have shown that the prevention of the nuclear translocation of ERK inhibits nucleus-dependent processes and pathologies without affecting the cytoplasmic activities of the kinase, and therefore, this inhibition has less side effects or resistance development than the currently used drugs. Our studies established that the nuclear translocation of ERK is mediated by Imp7, and prevention of the interaction between the two proteins blocks the nuclear ERK translocation, and as a consequence, inhibits the growth of many cancers. In the current presentation I will describe our recent studies on the regulation of the nuclear ERK translocation, and how can our finding be used as a new strategy to combat cancer.
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Cancer Science & Therapy.
Perspective · 21 Feb 2026
Finding Potential Passerini Adducts for Anticancer Drug Development
Perspective · 21 Feb 2026
Head and Neck Cutaneous Squamous Cell Carcinoma with Perineural Invasion
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalCancer Science & Therapy
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Rony Seger”
